A 205804 |
| Catalog No.GC15557 |
A 205804 is a potent and selective lead inhibitor of E-selectin and ICAM-1 expression (E-selectin: IC50 = 20nM; ICAM-1: IC50 = 25nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 251992-66-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
A 205804 is a potent and selective lead inhibitor of E-selectin and ICAM-1 expression (E-selectin: IC50 = 20nM; ICAM-1: IC50 = 25nM) [1]. A 205804 exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing the expression of E-selectin and ICAM-1 [1-2]. A 205804 is often used in the study of chronic inflammatory diseases [3].
In H9 cells, as the dose of A 205804 (1, 3, 5, and 10μM; 24h) increased, the expression level of ICAM-1 protein decreased [4]. In MDA-MB-231 cells, A 205804 (1 and 10μM; 12h) treatment reduced the expression of ICAM-1, whereas the expression of FAK, Src, paxillin, and heparanase was not affected [5].
In pancreatitis mice model, Lung tissue pathological damage, neutrophil infiltration, and pulmonary edema were significantly alleviated in mice after A 205804 (10mg/kg; po; 2 weeks) treatment [6]. In C56BL/6 mice, A 205804 (10mg/kg; po; 2 weeks) treatment of mice can effectively reduce the expression of E-selectin in endothelial vascular microenvironment cells [7]. In H1975 cell xenograft mouse model, A 205804 (10mg/kg; po; 2 weeks) blocks ICAM-1 and p-Cortactin expression by inhibiting the activity of Erβ [8].
References:
[1]. Stewart AO, Bhatia PA, McCarty CM, et al. Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression. Journal of medicinal chemistry. 2001 Mar 15; 44(6): 988-1002.
[2]. Yu R, Hou C, Peng Y, et al. The mechanism underlying ICAM-1 and E-selectin-mediated hypertriglyceridemic pancreatitis-associated lung injury. Molecular Immunology. 2022 Dec 1; 152: 55-66.
[3]. Liu F, Mao Y, Yan J, et al. Bionic microbubble neutrophil composite for inflammation-responsive atherosclerotic vulnerable plaque pluripotent intervention. Research. 2022 Jun 2.
[4]. Wu H, Tang X, Wang Y, et al. Dextran sulfate prevents excess aggregation of human pluripotent stem cells in 3D culture by inhibiting ICAM1 expression coupled with down-regulating E-cadherin through activating the Wnt signaling pathway. Stem Cell Research & Therapy. 2022 May 26; 13(1): 218.
[5]. Wei RR, Sun DN, Yang H, et al. CTC clusters induced by heparanase enhance breast cancer metastasis. Acta Pharmacologica Sinica. 2018 Aug;39(8):1326-1337.
[6]. Yu R, Hou C, Peng Y, Zhu X, Shi C, Huang D, Miao Y, Li Q. The mechanism underlying ICAM-1 and E-selectin-mediated hypertriglyceridemic pancreatitis-associated lung injury. Molecular Immunology. 2022 Dec 1; 152: 55-66.
[7]. Morita K, Tokushige C, Maeda S, et al. RUNX transcription factors potentially control E-selectin expression in the bone marrow vascular niche in mice. Blood Advances. 2018 Mar 13;2(5):509-515.
[8]. Wang Y, Qiu W, Chen J, et al. ERβ promoted invadopodia formation‐mediated non‐small cell lung cancer metastasis via the ICAM1/p‐Src/p‐Cortactin signaling pathway. International journal of cancer. 2023 Sep 15; 153(6): 1287-1299.
| Cell experiment [1]: | |
Cell lines | H9 cells |
Preparation Method | The H9 cells were dissociated into single cells by GCDR, seeded at 5000 cells per well in a 96-well plate coated with hESC-qualified Matrigel in the mTeSR1 medium supplemented with 10μM Y-27632, and allowed to settle overnight. The next day, the medium was changed and supplemented with different concentrations of A 205804. The cell viability was measured using a Cell Counting Kit-8 (CCK-8). CCK-8 reagent was added to each well and incubated for 1h, and the absorbance was read at 450nm and recorded using a microplate spectrophotometer. |
Reaction Conditions | 1, 3, 5, and 10μM; 24h |
Applications | As the dose of A 205804 increased, the expression level of ICAM-1 protein decreased. |
| Animal experiment [2]: | |
Animal models | Pancreatitis mice model |
Preparation Method | C57BL/6 mice were randomly divided into five groups: control group (Con), severe acute pancreatitis group (SAP), hypertriglyceridemic pancreatitis group (HTGP), A 205804 group (A 205804), and apocynin group (Apo). A total of 50 male mice were randomly allocated into five groups (n = 10 per group): Control group (Con), SAP group (SAP), HTGP group (HTGP), A 205804 group (A 205804) and Apocynin group (Apo). Mice in Con group and SAP group were fed with high-fat control diet (10kcal% fat, Research Diets, America) for 8 weeks, while the other groups were fed with high-fat diet (60kcal% fat). To establish the model of SAP, the mice received seven hourly intraperitoneal injections of cerulein (50μg/kg) dissolved in phosphate-buffered saline (PBS), and LPS (10mg/kg) was injected intraperitoneally 1h after the last cerulein administration. For the Con group, the same volume of saline was used to substituted for cerulein and LPS. In the A 205804 group, mice were given A 205804 (10mg/kg, dissolved in 1% dimethyl sulfoxide [DMSO] and 20% SBE-β-CD) orally, a potent and selective lead inhibitor of E-selectin and ICAM-1 expression. In the Apo group, apocynin was injected intraperitoneally (0.5mg/kg) 30 min prior to the SAP induction and the optimal dose was selected in agreement with the previous study. Subsequently, all mice were euthanized 24h after the first injection of cerulein, and blood samples, lung tissues and pancreatic tissues were obtained for further analysis. |
Dosage form | 10mg/kg; po; 2 weeks |
Applications | The pathological damage of lung tissue, neutrophil infiltration and pulmonary edema of mice in the A 205804 group were significantly alleviated. |
References: | |
| Cas No. | 251992-66-2 | SDF | |
| Chemical Name | 4-(4-methylphenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide | ||
| Canonical SMILES | CC1=CC=C(C=C1)SC2=C3C=C(SC3=CN=C2)C(=O)N | ||
| Formula | C15H12N2OS2 | M.Wt | 300.39 |
| Solubility | ≥ 30mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.329 mL | 16.645 mL | 33.2901 mL |
| 5 mM | 0.6658 mL | 3.329 mL | 6.658 mL |
| 10 mM | 0.3329 mL | 1.6645 mL | 3.329 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *